Mar. Drugs 2012, 10(5), 1138-1155; doi:10.3390/md10051138
Article

Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog

Xiangrong Zhang 1,† email, Hongxia Xu 1,† email, Xu Zhang 1 email, Sukesh Voruganti 1 email, Srinivasan Murugesan 2 email, Dwayaja H. Nadkarni 2 email, Sadanandan E. Velu 2 email, Ming-Hai Wang 3,4 email, Wei Wang 1,3,* email and Ruiwen Zhang 1,3,* email
1 Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA 2 Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA 3 Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA 4 Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA † These authors contributed equally to this work.
* Authors to whom correspondence should be addressed.
Received: 30 March 2012; in revised form: 2 May 2012 / Accepted: 16 May 2012 / Published: 23 May 2012
PDF Full-text Download PDF Full-Text [1025 KB, uploaded 23 May 2012 11:15 CEST]
Abstract: We have recently designed and synthesized a novel iminoquinone anticancer agent, 7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one (FBA-TPQ) and initiated its preclinical development. Herein we investigated its efficacy, safety, and pharmacokinetics in in vitro and in vivo models of human pancreatic cancer. Our results demonstrated that FBA-TPQ inhibited pancreatic cancer cell growth, induced apoptosis, and caused cell cycle arrest in vitro. It inhibited the growth of xenograft tumors with minimal host toxicity. To facilitate future preclinical and clinical development of the agent, we also developed and validated a Rapid Resolution Liquid Chromatography (RRLC) method for quantitative analysis of FBA-TPQ in plasma and tissue samples. The method was found to be precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of FBA-TPQ, including stability in plasma, plasma protein binding, metabolism by S9 enzymes, plasma pharmacokinetics, and tissue distribution. Our results indicate that FBA-TPQ is a potential therapeutic agent for pancreatic cancer, providing a basis for future preclinical and clinical development.
Keywords: pancreatic cancer; marine anticancer agents; RRLC; pharmacokinetics

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Zhang, X.; Xu, H.; Zhang, X.; Voruganti, S.; Murugesan, S.; Nadkarni, D.H.; Velu, S.E.; Wang, M.-H.; Wang, W.; Zhang, R. Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Mar. Drugs 2012, 10, 1138-1155.

AMA Style

Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang M-H, Wang W, Zhang R. Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Marine Drugs. 2012; 10(5):1138-1155.

Chicago/Turabian Style

Zhang, Xiangrong; Xu, Hongxia; Zhang, Xu; Voruganti, Sukesh; Murugesan, Srinivasan; Nadkarni, Dwayaja H.; Velu, Sadanandan E.; Wang, Ming-Hai; Wang, Wei; Zhang, Ruiwen. 2012. "Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog." Mar. Drugs 10, no. 5: 1138-1155.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert